On Thursday, Net Element International Inc (NASDAQ:NETE)’s shares declined -17.31% to $0.860.
Net Element International Inc (NETE) declared it has reached definitive agreements with a qualified institutional buyer and certain institutional accredited investors for financing transactions that will make an initial amount of $10.5 million and potential additional amounts of up to an additional $14 million accessible to the Company.
Following the definitive transaction documents for the first transaction, the Company has issued, as a registered direct offering, $5.5 million of Series A 9% Convertible Preferred Stock. Net Element will receive $5.5 million in gross proceeds at closing of this transaction. This transaction closed on April 30, 2015. Revere Securities LLC acted as the exclusive placement for the first transaction.
Net Element, Inc., a global payments-as-a-service, operates as a technology provider with an integrated mobile and transactional services platform serving emerging market clients. The company, through its partner, TOT Group, Inc., operates Unified Payments that processes cashless transactions for card-present or card-not-present transactions, counting point-of-sale (POS), mobile POS (mPOS), EMV, near field communication, Apple Pay, Internet businesses, service-oriented businesses, and mail order/telephone order merchants, in addition to processes other cashless transactions, counting checks and direct debits.
Emerald Oil Inc (NYSEMKT:EOX)’s shares dropped -16.34% to $0.711.
Emerald Oil Inc (EOX) declared financial and operational results for the quarter ended March 31, 2015.
Highlights
- First quarter production of 424,318 BOE raised 88% as contrast to 225,905 BOE in the first quarter of 2014. Daily production averaged 4,715 BOEPD, 14% above the midpoint and 10% above the high end of Emerald’s first quarter 2015 guidance range;
- Accomplished semi-annual borrowing base redetermination resulting in an elected commitment of $200 million;
Emerald Oil, Inc. operates as an independent oil and natural gas exploration and production company in the United States. The company designs, drills, and operates oil and natural gas wells.
At the end of Thursday’s trade, Tumi Holdings Inc (NYSE:TUMI)‘s shares dipped -15.77% to $19.71.
Tumi Holdings Inc (TUMI) declared its financial results for the first quarter ended March 29, 2015.
For the first quarter of 2015:
- Net sales raised 1.7% to $110.5 million from $108.6 million in the first quarter ended March 30, 2014. On a constant currency basis, net sales grew 4.6%.
- Total comparable store sales for all Direct-to-Consumer channels, counting company-owned websites, reduced 4.6%, contrast to an enhance of 5.3% in the first quarter of 2014.
- Direct-to-Consumer North America full-price comparable store sales declined 5.3%, outlet comparable store sales raised 1.1%, and e-commerce sales declined 14.1%.
Tumi Holdings, Inc. designs, produces, and markets a range of travel and business products, and accessories. It operates in four segments: Direct-to-Consumer North America; Direct-to-Consumer International; Indirect-to-Consumer North America; and Indirect-to-Consumer International.
Sequenom, Inc. (NASDAQ:SQNM), ended its Thursday’s trading session with -15.21% loss, and closed at $3.79.
Sequenom, Inc. (SQNM) stated total revenues of $37.8 million for the first quarter of 2015, an enhance of 2% contrast to revenues of $37.1 million for the first quarter of 2014.
Net earnings improved to $14.3 million, or $0.12 per share, basic and $0.11 per share, diluted, for the first quarter, as contrast to a net loss of $15.7 million, or $0.13 per share, basic and diluted, for the first quarter of 2014. The improvement in the net earnings from the preceding year is due to a $21.0 million gain on the pooled patents agreement with Illumina, Inc., in addition to improved gross margins and reduced operating expenses contrast to the preceding year first quarter.
Sequenom, Inc., a life sciences company, develops and commercializes molecular diagnostics testing services for the women’s health and oncology markets in the United States and internationally.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
